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Available online 11 June 2008The high-afﬁnity IgE receptor (FcεRI)-β gene is one of the atopy-associated genes, but its
biological signiﬁcance is largely unknown. In this study, we generated the anti-FcεRI-β chain
antibody to clarify β-chain protein expression in human mast cells. The FcεRI-β antibody
showed speciﬁc binding to a 27 kDa protein with Western blotting and membrane bound
immunostaining using cultured mast cells. Monomeric IgE sensitization increased β-chain
expression as well as mature α-chain expression in mast cells. Upregulation of β-chain
expression with monomeric IgE treatment suggests possible roles of FcεRI-β protein as an
atopy-related molecule.
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The high-afﬁnity IgE receptor (FcεRI)-β has been recog-
nized as an atopy-related gene (Cookson et al., 1989 and
Shirakawa et al., 1994). Some lines of study using a mouse
reconstitution system suggested that the FcεRI-β protein may
act as an ampliﬁer for mast mast-cell activation (Lin et al.,
1996). Mouse models are often useful tools for biomedical
research, but in the case of FcεRI-β, there are signiﬁcant
discrepancies between the mouse and human system. For
example, FcεRI-β protein expression is essential for cell-
surface expression of FcεRI in mice (Turner and Kinet, 1999),
however, human dendritic cells showed a cell-surface FcεRI
receptor without β-chain mRNA expression (Bieber et al.,st cells, bone-marrow-
ogy, Kyoto Prefectural
o-ku, Kyoto, 602-0841,
atsuda).
Y license. 1996). Therefore, the existence of FcεRI without β-chain
expression (FcεRI-αγ2 subtype) is probable in humans, but
not in mice (Hayashi et al., 1999). However, we could not
distinguish FcεRI-αβγ from FcεRI-αγ2 in situ due to the lack
of reliable anti-human FcεRI-β antibodies for histochemical
use. We chose to raise polyclonal rabbit antibodies to a
speciﬁc peptide of human FcεRI-β in order to help the
identiﬁcation of FcεRI-β protein. One such antibody prepara-
tion successfully bound to the expected 27 kDa band on
immunoblotting using human mast-cell/basophil lysate.
Another problem related to the functional study of human
FcεRI-β protein is a lack of good human cell lines which
express FcεRI. Human peripheral-blood-derived basophils
and mast cells had been so far recognized as the source for
FcεRI, however, the amounts of the cells were practically not
sufﬁcient for protein analysis. Recently, Kirshenbaum et al.
(2003) had established a cell line (LAD2) from a human
mastocytoma patient, which retains the character of native
human mast cells and expresses functional FcεRI. Using the
LAD2 cell line, we further proceeded to verify the speciﬁcity of
the antibody with immunoblotting and immunoprecipitation
studies. The new antibody reacted with FcεRI-β protein and
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2. Materials and methods
2.1. Antibodies
A rabbit anti-serum against unique C-terminal sequences of
FcεRI-β (CYSELEDPGEMSPPIDL) was generated by Afﬁnity
ResearchProducts Ltd. (Exeter, UK). Theanti-serumwaspuriﬁed
on a protein-A column (Amersham Plc., Little Chalfont, UK).
Other antibodies used in this study included Alexa 488-goat
anti-rabbit-F(ab′)2 and Alexa 594-goat anti-mouse IgG-F(ab′)2
(Invitrogen, Carlsbad, CA, USA), chimeric anti-NIP IgE antibody
(Serotec, Oxford, UK), rabbit anti-FcεRI-α and rabbit anti-FcεRI-
γ polyclonal antibodies (Upstate Biotechnology, Lake Placid,
USA), and mouse anti-FcεRI-α monoclonal antibody (clone:
CRA1; Kyokuto Pharmaceuticals, Tokyo, Japan).
2.2. Reagents
Reagents used in this study included Kaleidoscope
Prestained Protein Standards (Bio-Rad Japan, Tokyo, Japan),
Tris–glycine gels (Invitrogen), sodium dodecyl sulfate (SDS),
DL-dithiothreitol (DTT), and phosphatidylserine, alcian blue
dye (Sigma Japan, Tokyo, Japan), 3-Cyclohexylamino-1-pro-
panesulfonic acid (CAPS; Dojindo, Kumamoto, Japan), com-
plete mini protease cocktail tablet (Roche Ltd., Penzberg,
Germany), and HCL Plus Western blotting detection reagents
(Amersham). All other reagents used in this study were of
analytical grade.
2.3. Cell culture
Human basophils and eosinophils were puriﬁed from
venous blood with a basophil isolation kit or with anti-CD16
beads, respectively, withMidiMACS (Miltenyi Biotec, Gladbach,
Germany). Bone-marrow-derived CD34+cells were purchased
from Cambrex North Brunswick, Inc. (North Brunswick, NJ) and
bone-marrow-derived mast cells (b-mast) were generated as
previously described (Saito et al., 2006). Human blood samples
were collected from volunteers with written informed con-
sents, and all procedures were approved by the ethical
committees of Kyoto Prefectural University of Medicine and in
accordance with the Declaration of Helsinki. Purity of the
basophils and eosinophils was checked with alcian blue
staining and Hansel staining (Eosino-Stain; Tori-Pharmaceuti-
cals, Tokyo, Japan), respectively, and each showed a N98%
purity. Humanmastmast-cell line LAD2was kindly providedby
Dr. Arnold Kirshenbaum (NIAID, NIH) and maintained as
previously described (Kirshenbaum et al., 2003).
2.4. SDS-polyacrylamide gel electrophoresis (PAGE) and Western
blotting
LAD2 cells, eosinophils, and basophils were collected,
washed twice with phosphate-buffered saline (PBS), and the
number of cells was counted. Cells in the amount of 2×104
were then solubilized in SDS-sample buffer (62.5 mM Tris–
HCl, pH6.8, 2%SDS, 20% Glycerol, and 0.04% bromophenol
blue). Next, 50 mM DTT was added to the samples andincubated 15 min at 65 °C. Of each sample, 15 ml was loaded
to 12% Tris–glycine gel with Kaleidoscope prestained protein
standards. SDS-PAGE and Western blotting were then
performed. The electrophoresed protein was transferred to
polyvinylidene ﬂuoride (PVDF) membrane (Pall Japan, Tokyo,
Japan) using CAPS transfer buffer (10 mM CAPS, pH8.6, and
10% methanol). The membrane was then incubated with
primary antibodies (1:1000 dilution in 1% non-fat skim milk)
overnight at 4 °C with constant agitation. After washing with
PBS containing 0.05% Tween 20 (PBST), the membrane was
incubated with a 1:10,000 dilution of HRP conjugated anti-
rabbit IgG. (Amersham) for 1 h and then visualized with ECL
Plus Western blotting reagents.
2.5. Immunoprecipitation and subsequent immunoblotting
LAD2 cells in the amount of 2×107 were collected and
washed twicewith PBS, and then solubilized with 2ml of lysis
buffer (2 mM L-α-phosphatidylcholine, 10 mM CHAPS,
150 mM NaCl, and 50 mM Tris Tris–HCl pH 8.0 with a
complete mini protease inhibitor tablet) and centrifuged at
15,000 rpm for 30 min at 4 °C. The supernatant of the LAD2-
cell lysate was pre-cleared with protein-G sepharose for
30 min. Then the supernatant was separated in half, and 1 μg
of mouse anti-FcεRI-α monoclonal antibody or the same
amount of isotype-matched control (mouse IgG2a) was added
to each supernatant. After a 3-hour incubation at room
temperature (RT), protein-G sepharosewas added and further
incubated for 1 h. The protein-G beads were washed 5 times
with lysis buffer, then immunoprecipitated protein was
solubilized with 50 μl of SDS-sample buffer. The immunopre-
cipitated protein samples were immunoblotted with anti-
FcεRI-β and -γ antibodies as described above.
2.6. Flowcytometry and confocal microscopy analysis
LAD2, b-mast cells, and eosinophils were washed with PBS
twice and ﬁxed with 4% paraformaldehyde (PFA) in PBS for
15 min on ice. After PBS washing, the cells were permeabi-
lized with 0.1% saponin in blocking buffer (10% normal goat
serum, 1% bovine serum albumin in PBS) for 30 min on ice.
Non-speciﬁc Fc receptor binding was blocked using an Fc
receptor blocking reagent (Miltenyi Biotec). The cells were
then washed again with PBS and incubated with anti-FcεRI-β
IgG antibody (at the concentration of 20 μg/ml in blocking
buffer) for 15 min at RT. As a negative control, the same
amount of rabbit IgG (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) was used. After PBS washes, the samples were
incubated with 1 μg/ml of Alexa 488 conjugated anti-rabbit
antibody for 30 min. The stained LAD2 cells were also
analyzed with a FACS caliber (Becton Deckinson Japan,
Tokyo, Japan). For double-staining with FcεRI-α, the ﬁxed
LAD2 and b-mast cells were treated with Fc receptor blocking
reagents, then incubated with mouse anti-FcεRI-α mono-
clonal antibody and post-ﬁxed with 4% PFA-PBS. The cells
were then permeabilized with saponin and incubated with
the anti-FcεRI-β antibody. After PBS washes, the cells were
reacted with Alexa 488 conjugated anti-rabbit IgG and Alexa
594 conjugated anti-mouse IgG simultaneously. The stained
cells were then visualized with a confocal microscope (Fluo-
view 300; Olympus, Tokyo, Japan).
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FcεRI-β protein
LAD2 cells were sensitized with 0.5 μg/ml or 1.0 μg/ml of
NIP-IgE antibody for 24 h. After sensitization, the cells are
collected, washed twicewith PBS, and the number of cells was
counted. Cells in the amount of 4×104 were then solubilized
in SDS-sample buffer. SDS-PAGE and Western blotting was
were carried out either with rabbit anti-FcεRI-α or anti-FcεRI-
β polyclonal antibodies as described earlier. We quantiﬁed the
intensity of FcεRI-β positive bands by densitometry (NIH
image).
2.8. Reverse-transcription (RT) and real-time PCR analysis
Total RNA was isolated with the NucleoSpin RNA II
extraction kit (Macherey-Nagel, Duren, Germany) from
LAD2 cells, and then cDNA was prepared as described
previously (Shimizu et al., 2005). We used real-time PCR
probes and primers (Assay-on-Demand gene expression
products; Applied Biosystems, Foster City, CA, USA) speciﬁc
for human FcεRI-β(Hs00175091_m1) and FcεRI-
α(Hs00758599_m1), and GAPDH. Real-time PCR analysis
was carried out on a PRISM 7300 sequence detection system
(Applied Biosystems). The relative expression of FcεRI mRNA
in LAD2 cells was quantiﬁed by the standard curve method
using GAPDH expression in the same cDNA as a control.
3. Results
3.1. Western blotting of cell lysates with the anti-FcεRI-β
antibody
The 27 kDa single band was detected with basophil lysate
and LAD2 lysate, but not with eosinophil lysate (Fig. 1A). We
examined basophils and eosinophils from three healthy
volunteers. Although there was some variation of the FcεRI-
β protein protein-expression levels in basophils from subjectFig. 1. Immunoblotting and immunoprecipitation with the anti-FcεRI-β antibody. Im
27 kDa single band was observed with samples from basophils and LAD2 lysates, but
Electrophoresed LAD2-cell lysates were transferred to the same PVDF membrane an
antibody, and the remaining half (Lane 2) was incubated with the FcεRI-β antibod
subsequent Western blotting was performed (C and D). LAD2-cell lysate was imm
matched IgG2a antibody. The samples were electrophoresed in a non-reducing condi
with either the anti-FcεRI-β (C) or anti-FcεRI-γ chain (D) antibodies. Lane 1: a samp
sample immunoprecipitated with the control antibody.to subject, the results were essentially the same as this result
(data not shown). The detection was completely ablated with
the pre-incubation of the FcεRI-β antibody with a corre-
sponding peptide (Fig. 1B). Preimmune serum of the same
rabbit did not show any non-speciﬁc binding (data not
shown).
3.2. Immunoprecipitation and subsequent immunoblotting
The FcεRI-α immunoprecipitates were immunoblotted
with the anti-FcεRI-β antibody (Fig. 1C) and anti-FcεRI-γ
polyclonal antibody (Fig. 1D), and the corresponding single
band was observed by each blotting. No bands were observed
with the control sample immunoprecipitated with the
isotype-matched antibody.
3.3. Flowcytometry analysis and immunocytochemistry
LAD2 cells with saponin treatment incubated with the
FcεRI-β antibody showed positive staining by ﬂowcytometry
analysis compared to the negative control antibody staining.
The ﬁxed cells without saponin treatment showed negative
staining with the FcεRI-β antibody (Fig. 2A). Immunostained
LAD2 cells were also visualized by confocal microscopy, which
showed a membranous positive staining with the FcεRI-α
monoclonal antibody without cell permeabilization (Fig. 2B,
upper left). FcεRI-β staining needed subsequent saponin
treatment, and it showed membranous as well as some
cytoplasmic staining (Fig. 2B, upper right). Double-immunos-
taining using the FcεRI-β and the monoclonal FcεRI-α
antibody showed membranous colocalization (Fig. 2B, lower
right). Double-immunostaining with b-mast cells showed a
similar staining pattern to that of LAD2 cells (Fig. 3A). To rule
out non-speciﬁc immunostaining with the anti-FcεRI-β anti-
body after cell permeabilization, we checked the immunos-
taining of eosinophils with and without saponin treatments.
No deﬁnite immunostaining was observed even with per-
meabilized eosinophils (Fig. 3B).munoblotting was carried out with the anti-FcεRI-β antibody (A and B). The
not with eosinophils (A). Lane 1: basophil; Lane 2: eosinophil; Lane 3: LAD2.
d split into two pieces. One half (Lane 1) was incubated with the anti-FcεRI-β
y preincubated with the immunized peptide (B). Immunoprecipitation and
unoprecipitated with the anti-FcεRI-α chain (CRA-1) antibody or isotype-
tion and transferred onto a PVDFmembrane.Western blotting was performed
le immunoprecipitated with the anti-FcεRI-αmonoclonal antibody; Lane 2: a
Fig. 2. Flowcytometry and immunocytostaining with the anti-FcεRI-β antibody. (A) LAD2 cells were ﬁxed, permeabilized with saponin, and immunostained with
the anti-FcεRI-β antibody and Alexa 488 conjugated anti-rabbit IgG antibody. Normal rabbit IgG was used as a primary antibody for control staining (purple), anti-
FcεRI-β staining with saponin treatment (red), and anti-FcεRI-β staining without saponin treatment (green). Immunocytostaining with anti-FcεRI-β and -α
antibodies (B). Staining with FcεRI-β (green: upper left) staining and FcεRI-α (red: upper right), phase-contrast images (lower left) were merged with anti-FcεRI-
α/-β double-staining (lower right).
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The protein gradient wasmade according to the number of
LAD2 cells, and we found the linearity of FcεRI-β protein
immunoblotting at the range of 2.1×104 cells to 1.4×105 cells
(Fig. 4A). Then, the effect of monomeric IgE incubation for
FcεRI-β protein expression was examined. FcεRI-β protein
expression increased at 24 h after IgE incubation (Fig. 4B).Fig. 3. Immunocytostaining using b-mast cells and eosinophils with the anti-FcεR
(upper) and double immunostained with anti-FcεRI-α (red) and -β (green) antibod
eosinophils without permeabilization (upper left) or with permeabilization (lowerCoordinated FcεRI-α upregulation was also found, but no
difference for FcεRI-γ expression.
Real-time PCR analysis was also carried out to quantify
FcεRI-β and FcεRI-α mRNA expression at 24 h after mono-
meric IgE (1.0 μg/ml) stimulation. The relative FcεRI-β mRNA
expression ratio (monomeric IgE stimulation/mock stimula-
tion) was 1.017±0.109 (mean±SD) and the relative FcεRI-α
mRNA expression ratio was 0.726±0.027. The result is aI-β antibody. B-mast cells were immunostained with anti-FcεRI-β antibody
y (lower) (A). No positive anti-FcεRI-β immunostaining was observed using
left); phase-contrast images are shown at the right side (B).
Fig. 4. Quantiﬁcation of FcεRI subunit proteins by immunoblotting. Different numbers of LAD2 cells (2.1×104 cells to 1.6×105 cells, two-fold gradients) were
electrophoresed and immunoblotted with the anti-FcεRI-β antibody, and the intensity of the FcεRI-β positive band was quantiﬁed by densitometry (NIH image;
Fig. 2A). LAD2 cells were preincubated with monomeric IgE for 24 h, 4×104 cells were electrophoresed, then FcεRI-β, -α, and -γ protein expression was examined
by immunoblotting (Fig. 2B). Lane 1: naïve LAD2 cells; Lane 2: preincubated with 0.5 μg/ml IgE; Lane 3: preincubated with 1 μg/ml IgE.
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triplicate.
4. Discussion
We raised the anti-FcεRI-β polyclonal antibody against its C-
terminal peptides and conﬁrmed the speciﬁcity. Atﬁrstwemade
two anti-peptide polyclonal antibodies against both N-terminal
and C-terminal peptide sequences of the FcεRI-β protein,
respectively. We selected the C-terminal antibody to avoid
detecting the C-terminal truncated form of FcεRI-β(βT), which is
known to have an alternative effect for FcεRI functions
(Donnadieu et al., 2003). A single immunopositive band around
27 kDa with human basophils or mast-cell lysate was observed
byWesternblottingwith theanti-FcεRI-β antibodyand it didnot
react with eosinophil lysate (Fig. 1A). That result is reasonable
because FcεRI-β expression is abundant in mast cells and
basophils, but not in eosinophils (Seminario et al., 1999). A
neutralization experiment with the FcεRI-β antibody preab-
sorbed with the immunized peptide completely abolished the
27 kDa band (Fig. 1B). We also conﬁrmed the speciﬁcity by
Western blotting using the preimmune serum, which did not
showanybandswithmast-cell lysate (data not shown). Next,we
carried out co-immunoprecipitation of the FcεRI-αβγ complex
using the anti-FcεRI-αmonoclonal antibody with a lysis buffer
containing phospholipids as previously reported (Rivnay et al.,
1982) (Fig. 1C, D). The speciﬁcity of the FcεRI-β antibody was
further veriﬁed because it did react with the co-immunopreci-
pitated FcεRI-αβγ complex by immunoblotting.
Immunocytochemical staining and FACS analysis showed
that the FcεRI-β protein was expressed in the cell membrane
and cytoplasm of LAD2 cells (Fig. 2A and B). The FcεRI-α chainprotein was expressed on the cell surface and did not need
cell permeabilization for staining (Fig. 2B, upper right), but
the anti-FcεRI-β antibody did need cell permeabilization for
staining (Fig. 2B, upper left). Therefore, we immunostained
LAD2 cells in successive manners (the ﬁrst incubation with
the anti-FcεRI-α antibody was the non-permeabilized man-
ner, while the second incubation with the anti-FcεRI-β
antibody was carried out after saponin treatment). The
double-immunostaining (Fig. 2B, lower right) showed colo-
calization of FcεRI-α and FcεRI-β (yellow color) underneath
the cell cell-surface FcεRI-α staining (red color). These results
seemed to be reasonable because this anti-FcεRI-β chain
antibody was raised against the cytoplasmic portion of FcεRI-
β protein. Although the exact subcellular localization of
cytoplasmic FcεRI-β is still unknown, a previous report
showed that FcεRI-αβγ receptor complex were was pro-
cessed at endoplasmic reticulum (ER) and Golgi (Albrecht et
al., 2000), so the cytoplasmic part of our FcεRI-β staining in
LAD2 cells may reside in ER and Golgi. We also conﬁrmed the
FcεRI-α and FcεRI-β staining pattern in bone bone-marrow
progenitor-cell-derived mast cells (b-mast cells: Fig. 3A), and
speciﬁcity of immunocytostaining was further veriﬁed both
with permeabilized and non-permeabilized eosinophils
(negative controls: Fig. 3B).
As a next step, we showed that this FcεRI-β antibody is
useful for quantiﬁcation of the FcεRI-β protein within the
2.1×104 to 1.5×105 LAD2 cell range (Fig. 4A), making it
possible to evaluate quantitatively the effect of monomeric
IgE sensitization for the β-chain protein expression. Coordi-
nated upregulation of the FcεRI-β chain with the mature α-
chain (a hallmark for cell-surface FcεRI expression) had been
noted 24-hours after IgE stimulation (Fig. 4B). In addition, we
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response to monomeric IgE incubation and found that no
apparent FcεRI-α or FcεRI-β mRNA was induced with IgE
incubation. These results are consistent with the previous
reports which showed FcεRI upregulation after monomeric
IgE binding (Asai et al., 2001 and Yamaguchi et al., 1999), and
that monomeric IgE incubation did not upregulate FcεRI-α
and FcεRI-β promoter activity (Asai et al., 2001). Considering
two previous reports which showed that FcεRI-β protein has a
role as a stabilizer of FcεRI expression (Donnadieu et al.,
2000), and that the FcεRI-βγ complex supports FcεRI-α
insertion to ER and promotes cell-surface expression (Fiebiger
et al., 2005), we supposed that an increased FcεRI-β protein
expression in response to monomeric IgE contributes to
allergic reaction through the FcεRI stabilizing role.
The roles of FcεRI-β protein in mast cells are still
controversial. One previous report suggested its role as an
ampliﬁer (Lin et al., 1996), and another showed the role as an
inhibitory molecule (Gimborn et al., 2005) for degranulation
and cytokine expression. Further studies are necessary for
elucidating the roles of FcεRI-β protein, and of genetic
variants of the FcεRI-β gene over its protein-expression
control. This antibody will be a useful tool for elucidating
the pathophysiological signiﬁcance of FcεRI-β chain expres-
sion in atopic diseases.
Acknowledgements
We thank Ms. Hisako Takeshita for her excellent technical
assistance and Mr. John Bush for English language editing.
This study was supported in part by the Wellcome Trust
Traveling Research Fellowship (066797/Z/02/Z) to A.M., the
grants in aid for Scientiﬁc Research (programs 19659454 and
18604009) from the Japanese Ministry of Education, Culture,
Sports, Science and Technology, and for the Japanese National
Institute of Biomedical Innovation (Project ID05-24) program.
References
Albrecht, B., Woisetschlager, M., Robertson, M.W., 2000. Export of the high
afﬁnity IgE receptor from the endoplasmic reticulum depends on a
glycosylation-mediated quality control mechanism. J. Immunol. 165, 5686.
Asai, K., Kitaura, J., Kawakami, Y., Yamagata, N., Tsai, M., Carbone, D.P., Liu, F.T.,
Galli, S.J., Kawakami, T., 2001. Regulation of mast cell survival by IgE.
Immunity 14, 791.Bieber, T., Kraft, S., Jurgens, M., Strobel, I., Haberstok, J., Tomov, H., Regele, D.,
de la Salle, H., Wollenberg, A., Hanau, D., 1996. New insights in the
structure and biology of the high afﬁnity receptor for IgE (Fc epsilon RI)
on human epidermal Langerhans cells. J. Dermatol. Sci. 13, 71.
Cookson, W.O., Sharp, P.A., Faux, J.A., Hopkin, J.M., 1989. Linkage between
immunoglobulin E responses underlying asthma and rhinitis and
chromosome 11q. Lancet 1, 1292.
Donnadieu, E., Jouvin, M.H., Kinet, J.P., 2000. A second ampliﬁer function for
the allergy-associated Fc(epsilon)RI-beta subunit. Immunity 12, 515.
Donnadieu, E., Jouvin, M.H., Rana, S., Moffatt, M.F., Mockford, E.H., Cookson,
W.O., Kinet, J.P., 2003. Competing functions encoded in the allergy-
associated F(c)epsilonRIbeta gene. Immunity 18, 665.
Fiebiger, E., Tortorella, D., Jouvin, M.H., Kinet, J.P., Ploegh, H.L., 2005.
Cotranslational endoplasmic reticulum assembly of FcepsilonRI controls
the formation of functional IgE-binding receptors. J. Exp. Med. 201, 267.
Gimborn, K., Lessmann, E., Kuppig, S., Krystal, G., Huber, M., 2005. SHIP down-
regulates FcepsilonR1-induced degranulation at supraoptimal IgE or
antigen levels. J. Immunol. 174, 507.
Hayashi, S., Matsuda, H., Okumura, K., Ra, C., 1999. Mouse Langerhans cells do
not express the high-afﬁnity receptor for IgE. Arch. Dermatol. Res. 291, 241.
Kirshenbaum, A.S., Akin, C., Wu, Y., Rottem, M., Goff, J.P., Beaven, M.A., Rao, V.
K., Metcalfe, D.D., 2003. Characterization of novel stem cell factor
responsive human mast cell lines LAD 1 and 2 established from a patient
with mast cell sarcoma/leukemia; activation following aggregation of
FcepsilonRI or FcgammaRI. Leuk. Res. 27, 677.
Lin, S., Cicala, C., Scharenberg, A.M., Kinet, J.P., 1996. The Fc(epsilon)RIbeta
subunit functions as an ampliﬁer of Fc(epsilon)RIgamma-mediated cell
activation signals. Cell 85, 985.
Rivnay, B., Wank, S.A., Poy, G., Metzger, H., 1982. Phospholipids stabilize the
interaction between the alpha and beta subunits of the solubilized
receptor for immunoglobulin E. Biochemistry 21, 6922.
Saito, H., Kato, A., Matsumoto, K., Okayama, Y., 2006. Culture of human mast
cells from peripheral blood progenitors. Natl. Protoc. 1, 2178.
Seminario, M.C., Saini, S.S., MacGlashan Jr., D.W., Bochner, B.S., 1999.
Intracellular expression and release of Fc epsilon RI alpha by human
eosinophils. J. Immunol. 162, 6893.
Shimizu, M., Matsuda, A., Yanagisawa, K., Hirota, T., Akahoshi, M., Inomata, N.,
Ebe, K., Tanaka, K., Sugiura, H., Nakashima, K., Tamari, M., Takahashi, N.,
Obara, K., Enomoto, T., Okayama, Y., Gao, P.S., Huang, S.K., Tominaga, S.,
Ikezawa, Z., Shirakawa,T.,2005. Functional SNPs in thedistalpromoterof the
ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. 14, 2919.
Shirakawa, T., Li, A., Dubowitz, M., Dekker, J.W., Shaw, A.E., Faux, J.A., Ra, C.,
Cookson, W.O., Hopkin, J.M., 1994. Association between atopy and
variants of the beta subunit of the high-afﬁnity immunoglobulin E
receptor. Nat. Genet 7, 125.
Turner, H., Kinet, J.P., 1999. Signalling through the high-afﬁnity IgE receptor
Fc epsilonRI. Nature 402, B24.
Yamaguchi, M., Sayama, K., Yano, K., Lantz, C.S., Noben-Trauth, N., Ra, C.,
Costa, J.J., Galli, S.J., 1999. IgE enhances Fc epsilon receptor I expression
and IgE-dependent release of histamine and lipid mediators from human
umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE
on human mast cell Fc epsilon receptor I expression and mediator
release. J. Immunol. 162, 5455.
